^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent) + fludarabine IV (DNA synthesis inhibitor) + granulocyte-colony stimulating factor (GCSF) (Frataxin gene expression enhancer) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
AML:…Therapy for relapsed/refractory disease…aggressive therapy for appropriate patients…Fludarabine + cytarabine + G-CSF ± idarubicin
